| Prev Close | 119.18 |
| Open | 119.00 |
| Day Low/High | 114.74 / 119.81 |
| 52 Wk Low/High | 61.61 / 115.14 |
| Volume | 6.44M |
Abbott Laboratories (ABT)
116.01
3.17
2.66
NYSE
| Exchange | NYSE |
| Shares Outstanding | 1771.53B |
| Market Cap | 217.07B |
| P/E Ratio | 60.02 |
| Div & Yield | N.A. (N.A) |
Abbott Labs Passes Our Test
As it gets the OK for a new rapid Covid-19 detecting device, Abbott Labs could be purchased here following our new technical strategy.
Q2 Earnings Expectations, 4 Key Economic Questions, Trading Abbott Labs
I do believe that having no economy is temporary. I also believe that what comes out on the other side will be smaller, far less global.
Navigating These Times, Putting Cash to Work, Oil Price War, Trump Stimulus Plan
Markets appear stable. Do we trust it? Can we trust it? Of course not.
Jim Cramer: I Don't Know Where It Will Bottom, I Do Know What to Buy and Sell
This is the time to high grade your portfolio, take some losses and move to better stocks.
In This Market, Where Do We Draw the Line?
Everyone seems concerned that non-technology stocks are as vulnerable as the industrials and energy stocks.
Market Direction and Trading Volume, Resilient Boeing, Trading Costco
Boeing's new estimate for the FAA's signing off on returning the 737 MAX to commercial skies has been pushed out until summer, June or July? Is that really that bad? Perhaps... this is a positive.
Abbott Laboratories Could Climb to the $107 Area Next
Barring a negative surprise I would look for higher highs to be established in the days and weeks ahead.
The Week Ahead: Davos, Impeachment, PMI and 25 Key Earnings Reports to Watch
Almost 200 companies are slated to report quarterly results, including 43 S&P 500 constituents.
3 Boomer-Inspired Drug Plays With Dividend Appeal
Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.
A Fresh Look at Abbott Labs Still Shows a Long-Term Uptrend in Place
Let's review the charts of ABT.
Jim Cramer: Nothing's Changed, Except the Prices
The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.
Abbott Labs Has Concocted a Way to Advance Further
The medical device and health care company is set to resume its long advance, with our first price target at $92 and next at $100.
Markets Bet on Growth, 3 Month/10 Year Spread, Trading Nvidia: Market Recon
The Fed is doing this right. Let me repeat... the Fed is not screwing this up.
Jim Cramer: Watch for Stocks Reporting 'Not as Bad as Feared' Numbers
When you have an oversold market you've got a true coiled spring that can rally beyond where it might ordinary go on good news.
AbbVie: The Right Mixture for the Perfect Stock
ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.
U.S. Monetary Policy, Trading Lockheed, Netflix and United Rentals: Market Recon
Preventing the U.S. dollar from appreciating too aggressively while repairing credit conditions are 'job freaking one'.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Jim Cramer: These 7 True Laggards Have Caught Fire
These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.
Good News From China, Plus Netflix Earnings and Playing CSX: Market Recon
China reported positive data, bolstering markets. Netflix had a beat on earnings, but faces fierce competition ahead. CSX is a thing of beauty.
Trading Notes for Select Stocks
Here's my take on a list of stocks I've been watching.
Shares of Abbott Laboratories Poised for Upside Breakout
ABT is pointed up after trading in a choppy range since October.
An IBM Play and 2 Catalysts To Watch in Wednesday's Trading: Market Recon
Keeping an eye on the Senate shutdown vote and any trade discussion today, and watching key support levels on the SPX.
Jim Cramer: If We Get a China Deal, Then This Rally Is In Its Infancy
The kick will come from the Chinese capitulating because their economy is so weak.
New Favorites for 2019 from Last Year's Top Stock Pickers
Mike Cintolo and Jim Woods saw their top picks for 2018 rise 81% and 75%, respectively.
This 2019 Market Optimism Is Misplaced: Market Recon
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
Here Are 9 Takeaways From Last Night's Meltdown: Market Recon
It becomes difficult for me to tell you where to run in these markets...
Why Netflix Is a Good Name to Short on This Earnings Report: Market Recon
I am unimpressed by the latest earnings report. Despite good subscriber growth, fundamentals look weak.
